GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai ZJ Bio-Tech Co Ltd (SHSE:688317) » Definitions » Capex-to-Revenue

Shanghai ZJ Bio-Tech Co (SHSE:688317) Capex-to-Revenue : 0.26 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai ZJ Bio-Tech Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shanghai ZJ Bio-Tech Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-13.08 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥51.23 Mil.

Hence, Shanghai ZJ Bio-Tech Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.26.


Shanghai ZJ Bio-Tech Co Capex-to-Revenue Historical Data

The historical data trend for Shanghai ZJ Bio-Tech Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai ZJ Bio-Tech Co Capex-to-Revenue Chart

Shanghai ZJ Bio-Tech Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.04 0.25 0.03 0.30

Shanghai ZJ Bio-Tech Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 -0.13 0.27 0.46 0.26

Competitive Comparison of Shanghai ZJ Bio-Tech Co's Capex-to-Revenue

For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai ZJ Bio-Tech Co's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Capex-to-Revenue falls into.



Shanghai ZJ Bio-Tech Co Capex-to-Revenue Calculation

Shanghai ZJ Bio-Tech Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-81.146) / 274.333
=0.30

Shanghai ZJ Bio-Tech Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-13.077) / 51.227
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai ZJ Bio-Tech Co  (SHSE:688317) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Shanghai ZJ Bio-Tech Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai ZJ Bio-Tech Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai ZJ Bio-Tech Co (SHSE:688317) Business Description

Traded in Other Exchanges
N/A
Address
No. 588 Xinjun Ring Road, Building 26, Pujiang Hi-Tech Park, Caohejing Development Zone, Shanghai, CHN
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.

Shanghai ZJ Bio-Tech Co (SHSE:688317) Headlines

No Headlines